Duloxetine + Sugar pill
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Traumatic Brain Injury
Conditions
Traumatic Brain Injury, Depression
Trial Timeline
Sep 1, 1996 → Jul 1, 2011
NCT ID
NCT01223001About Duloxetine + Sugar pill
Duloxetine + Sugar pill is a phase 2 stage product being developed by Eli Lilly for Traumatic Brain Injury. The current trial status is terminated. This product is registered under clinical trial identifier NCT01223001. Target conditions include Traumatic Brain Injury, Depression.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01558700 | Approved | Completed |
| NCT01223001 | Phase 2 | Terminated |
Competing Products
20 competing products in Traumatic Brain Injury
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Neurosteroid enantiomer | Oragenics | Phase 2 | 44 |
| Celecoxib | Astellas Pharma | Pre-clinical | 23 |
| Mupirocin Calcium Cream, 2% + Bactroban® Cream + Cream vehicle of test product | Sun Pharmaceutical | Phase 1 | 33 |
| Duloxetine hydrochloride | Eli Lilly | Phase 3 | 77 |
| Galcanezumab-Gnlm | Eli Lilly | Approved | 85 |
| SYN117 (nepicastat) + Placebo comparator | Johnson & Johnson | Phase 2 | 52 |
| Nepicastat + Placebo | Johnson & Johnson | Phase 2 | 52 |
| JNJ-17299425 | Johnson & Johnson | Phase 2 | 52 |
| Placebo + sertraline | Johnson & Johnson | Approved | 85 |
| Quetiapine Fumarate + quetiapine fumarate placebo | AstraZeneca | Phase 3 | 77 |
| Adjunctive asenapine | Merck | Approved | 85 |
| Rizatriptan + Placebo | Merck | Pre-clinical | 23 |
| Alendronate | Merck | Approved | 85 |
| Iloperidone + Placebo | Novartis | Phase 2 | 52 |
| AMG 334 | Novartis | Phase 2 | 52 |
| Rivastigmine | Novartis | Phase 3 | 77 |
| Rivastigmine | Novartis | Approved | 85 |
| Balovaptan + Placebo | Roche | Phase 2 | 52 |
| Erenumab | Amgen | Phase 2 | 51 |
| Growth Hormone | Novo Nordisk | Phase 2 | 51 |